T-MAXIMUM PHARMACEUTICAL, a biotechnology company specialising in universal cell-based therapies, has received international praise for its pioneering work in allogeneic CAR-T cell therapy.MT027, the lead product in T-MAXIMUM’s pipeline, is an allogeneic CAR-T therapy modified using CRISPR/Cas9 technology to target the B7-H3 tumour antigen in recurrent glioblastoma and other solid tumours.

T-MAXIMUM PHARMACEUTICAL是一家专注于通用细胞疗法的生物技术公司，因其在异基因CAR-T细胞疗法方面的开创性工作而受到国际赞誉。MT027是T-MAXIMUM管道中的主要产品，是一种使用CRISPR/Cas9技术修饰的同种异体CAR-T疗法，用于靶向复发性胶质母细胞瘤和其他实体瘤中的B7-H3肿瘤抗原。

Early studies have shown it to be both effective and safe. MT027 could potentially treat various late-stage solid tumours, offering hope to patients with aggressive cancers.T-MAXIMUM is preparing MT027 for registration and clinical trials in the United States, with manufacturing already finalised and partnerships established with third-party manufacturers in China and the United States.

早期研究表明它既有效又安全。MT027可能会治疗各种晚期实体瘤，为侵袭性癌症患者带来希望。T-MAXIMUM正在准备MT027在美国进行注册和临床试验，生产已经完成，并与中国和美国的第三方制造商建立了合作伙伴关系。

The product has received Orphan Drug Designation from the US FDA, which could expedite its approval process. In addition to MT027, the company is developing two other allogeneic CAR-T therapies: MT026, targeting IL13Rα2 for solid tumours, and MT020, aimed at treating B-cell related autoimmune diseases.T-MAXIMUM, has also announced the development of next-generation allogeneic CAR-T therapies for solid tumours, which will involve more advanced T-cell engineering.

该产品已获得美国FDA的孤儿药指定，这可能会加快其批准过程。除MT027外，该公司正在开发另外两种同种异体CAR-T疗法：针对实体瘤的IL13Rα2的MT026和旨在治疗B细胞相关自身免疫性疾病的MT020。T-MAXIMUM还宣布开发用于实体瘤的下一代同种异体CAR-T疗法，这将涉及更先进的T细胞工程。

The company is exploring strategies to combine CAR-T cells with other treatments to improve disease control in advanced solid tumours, ultimately aiming to transform these tumours into manageable chronic conditions.Traditional CAR-T cell therapies typically use a patient’s own cells, which can be time-consuming and expensive to produce.

该公司正在探索将CAR-T细胞与其他治疗方法相结合的策略，以改善晚期实体瘤的疾病控制，最终旨在将这些肿瘤转化为可控制的慢性病。传统的CAR-T细胞疗法通常使用患者自己的细胞，这可能耗时且昂贵。

This method also carries risks, including the potential for manufacturing failures and insufficient T cells in patients who have undergone extensive treatments. In contrast, allogeneic CAR-T therapies use T cell.

这种方法也存在风险，包括接受广泛治疗的患者可能出现制造失败和T细胞不足。相反，同种异体CAR-T疗法使用T细胞。